

August 2, 2016

---

## Nippon Shokubai Announces to Form a Capital Alliance with TAK-Circulator

NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Japan, President: Masanori Ikeda, hereinafter “Nippon Shokubai”) announces that Nippon Shokubai has decided to subscribe for shares of TAK-Circulator Corporation (Headquarter: Tokyo, Japan, President: Asuka Morikawa, hereinafter “TAK-Circulator”) through a third party allotment.

### 1. Purpose of the Alliance

In the current long term business plan “Reborn Nippon Shokubai 2020” started in 2014, Nippon Shokubai has a plan to add a health and medical business sector as a new business area. Nippon Shokubai is building a drug development support business to provide customers a consistent service from drug discovery & clinical studies to contract manufacturing. In addition to peptide drugs and DDS category, in which Nippon Shokubai is already developing business, Nippon Shokubai is targeting nucleic acid drugs as a next drug category. Nippon Shokubai keeps on seeking out chances of business partnerships with those who has innovative seeds in these fields.

TAK-Circulator was established to apply research outcomes of University of Tokyo. TAK-Circulator’s core businesses are microbiome analysis business based on next generation sequencing analysis and nucleic acid drug discovery business to contribute on health and longevity.

Nippon Shokubai will accelerate TAK-Circulator’s drug development business through capital alliance and consider the possibility of collaboration with respect to development and manufacturing of these drugs between Nippon Shokubai and TAK-Circulator.

### 2. Outline of the Alliance

Class and numbers of shares to be subscribed	: 16,000 shares of common stock
Share-holding after subscription	: 21.42%
Payment date	: August 25th, 2016

### 3. Outline of TAK-Circulator

Name	TAK-Circulator Corporation
Head Office	704 Entrepreneur plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
Representative	Asuka Morikawa, M.D.
Activity	Microbiome analysis business based on next generation sequencing analysis. Drug discovery business to contribute on health and longevity.
Capital	170.25 million yen
Established	January 17th, 2014
Numbers of shares outstanding	58,700 shares
End of fiscal year	December 31 <sup>st</sup>
Employees	8 (as of June 2016)
Website	<a href="http://www.tak-circ.com/en/">http://www.tak-circ.com/en/</a>

### 4. Forecast

Nippon Shokubai will consider further possibility of business collaboration with TAK-Circulator. At the same time, Nippon Shokubai will keep on seeking out of the possibility of further partnerships in order to construct a drug development support business.

---

**【Contacts】** Investor & Public Relations Dept.  
NIPPON SHOKUBAI CO., LTD.  
TEL: +81-3-3506-7605 E-mail: [shokubai@n.shokubai.co.jp](mailto:shokubai@n.shokubai.co.jp)